SOCS ELISA Kits
Suppressor of Cytokine Signaling (SOCS) proteins are critical regulators of cytokine signaling pathways, modulating immune responses and maintaining cellular homeostasis. Dysregulation of SOCS proteins is implicated in various diseases, including autoimmune disorders, cancers, and inflammatory conditions.
- Specificity: Each kit is tailored to detect a particular SOCS protein (e.g., SOCS1, SOCS3), ensuring precise measurement without cross-reactivity.
- Sensitivity: Designed to detect low concentrations of SOCS proteins, with detection limits often in the picogram per milliliter (pg/mL) range.
- Sample Compatibility: Validated for use with various sample types, including human, mouse, rat, and bovine specimens, facilitating cross-species research.
Applications:
- Biomedical Research: Investigating the role of SOCS proteins in disease mechanisms, such as their involvement in cancer progression, autoimmune diseases, and metabolic disorders.
- Drug Development: Assessing the impact of therapeutic agents on SOCS expression levels, aiding in the development of treatments targeting cytokine signaling pathways.
- Clinical Diagnostics: Potential use in identifying biomarkers for disease states characterized by altered SOCS expression, contributing to diagnostic and prognostic evaluations.
Examples of SOCS ELISA Kits:
- Human SOCS1 ELISA Kit: Designed for the quantitative detection of human SOCS1 in various sample types, with a sensitivity of 0.094 ng/mL and a detection range of 0.156–10 ng/mL. Antibodies
- Mouse SOCS3 ELISA Kit: Enables the measurement of mouse SOCS3 levels in plasma and serum, with a sensitivity of 0.16 ng/mL and a detection range of 0.16–10 ng/mL. Lsbio
These kits are indispensable tools for researchers aiming to elucidate the complex roles of SOCS proteins in health and disease, providing reliable and reproducible data essential for advancing our understanding of cytokine signaling regulation.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|